RCUS Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -321.21% compared to Arcus Biosciences, Inc.'s net margin of 27.44%. Arcus Biosciences, Inc.'s return on equity of -67.06% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Arcus Biosciences, Inc. has a consensus price target of $33.70, signalling upside risk potential of 40.77%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $156.59 which suggests that it could grow by 4.37%. Given that Arcus Biosciences, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Arcus Biosciences, Inc. is more attractive than Gilead Sciences, Inc..

Arcus Biosciences, Inc. has a beta of 0.847, which suggesting that the stock is 15.303% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.44%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.11% to investors and pays a quarterly dividend of $0.79 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.6% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences, Inc. quarterly revenues are $33M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $8B. Arcus Biosciences, Inc.'s net income of -$106M is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 22.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.42x versus 6.40x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -321.21% compared to Arcus Biosciences, Inc.'s net margin of 34.4%. Arcus Biosciences, Inc.'s return on equity of -67.06% beat Eli Lilly & Co.'s return on equity of 104.39%.

Arcus Biosciences, Inc. has a consensus price target of $33.70, signalling upside risk potential of 40.77%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 19.29%. Given that Arcus Biosciences, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Arcus Biosciences, Inc. is more attractive than Eli Lilly & Co..

Arcus Biosciences, Inc. has a beta of 0.847, which suggesting that the stock is 15.303% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences, Inc. quarterly revenues are $33M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Arcus Biosciences, Inc.'s net income of -$106M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 45.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.42x versus 14.23x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -321.21% compared to Arcus Biosciences, Inc.'s net margin of 18.15%. Arcus Biosciences, Inc.'s return on equity of -67.06% beat Merck & Co., Inc.'s return on equity of 36.76%.

Arcus Biosciences, Inc. has a consensus price target of $33.70, signalling upside risk potential of 40.77%. On the other hand Merck & Co., Inc. has an analysts' consensus of $127.21 which suggests that it could grow by 4.78%. Given that Arcus Biosciences, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Arcus Biosciences, Inc. is more attractive than Merck & Co., Inc..

Arcus Biosciences, Inc. has a beta of 0.847, which suggesting that the stock is 15.303% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.269, suggesting its less volatile than the S&P 500 by 73.077%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences, Inc. quarterly revenues are $33M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Arcus Biosciences, Inc.'s net income of -$106M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.42x versus 4.69x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -321.21% compared to Arcus Biosciences, Inc.'s net margin of 21.74%. Arcus Biosciences, Inc.'s return on equity of -67.06% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Arcus Biosciences, Inc. has a consensus price target of $33.70, signalling upside risk potential of 40.77%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $870.73 which suggests that it could grow by 10.11%. Given that Arcus Biosciences, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Arcus Biosciences, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Arcus Biosciences, Inc. has a beta of 0.847, which suggesting that the stock is 15.303% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.484%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.94 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences, Inc. quarterly revenues are $33M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Arcus Biosciences, Inc.'s net income of -$106M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.42x versus 5.99x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.